---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-033282"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-08-17T13:05:22+00:00"
generated_at: "2026-08-17T13:06:17.217700+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BridgeBio secondary offering: KKR sells 5M shares at $78, no proceeds to company

## Summary
- KKR Genetic Disorder L.P. selling 5,000,000 shares at $78.00/share; expected close Aug 17, 2026.
- Company receives no proceeds; offering oversubscribed per Aug 14 press release.
- Joint book-runners: William Blair, Goldman Sachs & Co. LLC, KKR Capital Markets LLC.
- Offering launched Aug 13, priced Aug 14; aims to diversify shareholder base toward long-term ownership.

## SEC filing metadata
- accession: 0001140361-26-033282
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-08-17T13:05:22+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036126033282/0001140361-26-033282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126033282/ef20080234_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-033282
- JSON: https://secwatch.observer/filing/0001140361-26-033282.json
- Plain text: https://secwatch.observer/filing/0001140361-26-033282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.